JKConsulting

21/05/2017

26/04/2017

Redx Pharma secures $1m grant for bacteria research https://t.co/D8iRlxf7Zo

Redx Pharma has secured a $1m grant fromCARB-X, one of the world’s largest public-private partnerships, launched in July 2016 to speed up global antibacterial innovation and research.

23/02/2017

I love ! Sign up with my link and get 50 free email credits! https://t.co/tHEXoLDwZN via

SellHack is a sales prospecting tool with a browser extension to build prospect lists. Verify email addresses and phone numbers. Export your leads and start sending cold emails.

20/02/2017

Reinventing Life Science Startups: Evidence-Based Entrepreneurship via https://t.co/BSwvK18upF

What if we could increase productivity and stave the capital flight by helping Life Sciences startups build their companies more efficiently? We’re going to test this hypothesis by teaching a Lean LaunchPad class for Life Sciences (therapeutics, diagnostics, devices and digital health) this October…

11/02/2017

https://t.co/D3u91SL55x

Investors lose billions as immunotherapies fall short of high expectations

07/02/2017

Scientists Have Figured Out How Our Brains Sharpen Our Memories While We Sleep https://t.co/UnSFAcMXVp via

We all know that if we want what we've studied during the day to stick, it's best to get a good night's sleep. And while scientists have long understood that our memories rely on connections being built between neurons in our brains, it's not been...

06/02/2017

To Be - or Not To Be, a Virtual Biotech? https://t.co/FlnjuiKCKc via

Many new biotechs start off as virtual companies. But at each stage of development, you always end up asking whether you should stay virtual or build your own in-house wet labs. What are the pros and cons of being virtual? ...

06/02/2017

Study Shows Which Treatments OCD Patients Prefer, and Why https://t.co/RXxaxNGk3h

Factors such as a patient’s age, gender, income, beliefs, and concerns can influence which treatments they choose for obsessive compulsive disorder (OCD) and may help inform the planning of more successful treatment, suggests new research published in Psychiatric Services.

02/02/2017

https://t.co/ZinLQ1m56G

Today, BIO CEO Jim Greenwood delivered a key message to the Indian government and Prime Minister Damodardas Modi at an economic development conference in Gandhinagar: Successful innovation results …

25/01/2017

BRIEF-Biotest to sell US therapy business to ADMA Biologics Inc. - https://t.co/GbM8AwJ4cq

Biotest AG :

24/01/2017

https://t.co/WPiseeNlnP

Eternygen has received €8M in a Series A round led by Epidarex Capital that will be used to advance its pipeline in collaboration with Evotec. Eternygen is a young biotech in Berlin focusing on the treatment of metabolic diseases. The company ...

24/01/2017

PharmAthene and Altimmune to Merge in All-Stock Deal - https://t.co/bFYt0RRBdN

The two Maryland biotech companies will merge in an all-stock transaction.

24/01/2017

New hope for children with brain tumors https://t.co/eGHy23J6X7 via

A new study out of Harvard-affiliated Dana-Farber/Boston Children’s Cancer and Blood Disorders Center suggests that precision medicine can provide vital care in treatment and diagnosis of pediatric brain tumors.

23/01/2017

Failed Mergers Cast Shadow on Sanofi's Future - https://t.co/f8Usnsc3xE

Two failed acquisitions have cast a long shadow on Sanofi's prospects.

23/01/2017

BRIEF-Eagle Pharmaceuticals completes NDA submission for Ryanodex - https://t.co/xBuC24LcbH

Eagle Pharmaceuticals Inc

23/01/2017

Cervical Cancer Death Rates Are Much Higher Than Thought, Study Says - https://t.co/4uNzDz4qv3

The risk of dying from cervical cancer might be much higher than experts previously thought, and women are encouraged to continue recommended cancer screenings.

23/01/2017

Where is Trump?????Eli Lilly to Lay Off 485 Workers https://t.co/VTxYs5IjPU

Because of an Alzheimer's drug failure, Lilly USA announced nationwide layoffs

23/01/2017

This year’s JPM roundup: deals, lack of deals, a different breed of startup, and a Trump card https://t.co/MnmKDd1sXX

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on the lookout for deals, critical updates, and using the conference as a litmus test for what the year ahead may bring.